Fox Run Management’s Vaxcyte PCVX Stock Holding History

Fox Run Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247K	Buy	+4,248	New	+$231K	0.04%	746
2025 Q4	–	Sell	-5,699	Closed	-$205K	–	1176
2025 Q3	$205K	Buy	+5,699	New	+$189K	0.03%	799
2025 Q2	–	Sell	-34,228	Closed	-$1.29M	–	1134
2025 Q1	$1.29M	Buy	34,228 +30,239	+758%	+$2.42M	0.2%	120
2024 Q4	$327K	Buy	+3,989	New	+$396K	0.06%	602
2023 Q2	–	Sell	-6,768	Closed	-$254K	–	892
2023 Q1	$254K	Buy	+6,768	New	+$287K	0.08%	460

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fox Run Management's PCVX Position: Q2 2026 in Review

Fox Run Management opened a new position in Vaxcyte (PCVX) in Q2 2026: 4,248 shares worth $247K. The stake represents 0.04% of the portfolio and ranks #746 among its holdings. This is a return to the name: Fox Run Management previously reported a position in PCVX as recently as Q3 2025.

Fox Run Management first reported a position in PCVX in Q1 2023 and has held it in 5 quarters since. The position peaked at $1.29M in Q1 2025. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Fox Run Management held 4,248 shares of Vaxcyte worth $247K as of Q2 2026.
Vaxcyte was a new Fox Run Management position in Q2 2026.
Vaxcyte made up 0.04% of Fox Run Management's portfolio in Q2 2026, its #746 holding.
Fox Run Management first reported a position in Vaxcyte in Q1 2023 and has held it in 5 quarters since.
Fox Run Management's Vaxcyte position peaked at $1.29M in Q1 2025.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.